Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents
The first line of glaucoma treatment focuses on reducing intraocular pressure (IOP) through the prescription of topical prostaglandin analogues, such as latanoprost (LAT). Topical ophthalmic medicines have low bioavailability due to their rapid elimination from the ocular surface. Nanotechnology off...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2024 |
| País: | España |
| Recursos: | Universidad Complutense de Madrid (UCM) |
| Repositório: | Docta Complutense |
| Idioma: | inglês |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/104619 |
| Acesso em linha: | https://hdl.handle.net/20.500.14352/104619 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Glaucoma Hyaluronic acid Latanoprost Liposomes Ocular drug delivery Osmoprotectants Optica (Medicina) 2209.15 Optometría |
| id |
ES_0839742d21bc2b6802eea6a76bd32ef3 |
|---|---|
| oai_identifier_str |
oai:docta.ucm.es:20.500.14352/104619 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agentsBrugnera, MarcoVicario De La Torre, MartaGonzález-Cela Casamayor, Miriam AnaLópez Cano, José JavierBravo Osuna, IreneHuete Toral, FernandoGonzález Rubio, María LuisaCarracedo Rodríguez, Juan GonzaloMolina Martínez, Irene TeresaAndrés Guerrero, VanesaHerrero Vanrell, María Del RocíoGlaucomaHyaluronic acidLatanoprostLiposomesOcular drug deliveryOsmoprotectantsOptica (Medicina)2209.15 OptometríaThe first line of glaucoma treatment focuses on reducing intraocular pressure (IOP) through the prescription of topical prostaglandin analogues, such as latanoprost (LAT). Topical ophthalmic medicines have low bioavailability due to their rapid elimination from the ocular surface. Nanotechnology offers innovative ways of enhancing the ocular bioavailability of antiglaucoma agents while reducing administration frequency. This study aims to combine LAT-loaded synthetic phosphatidylcholine liposomes with hyaluronic acid (0.2% w/v) and the osmoprotectants betaine (0.40% w/v) and leucine (0.90% w/v) (LAT-HA-LIP) to extend the hypotensive effect of LAT while protecting the ocular surface. LAT-HA-LIP was prepared as a mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol and α-tocopherol acetate. LAT-HA-LIP exhibited high drug-loading capacity (104.52 ± 4.10%), unimodal vesicle sizes (195.14 ± 14.34 nm) and a zeta potential of -13.96 ± 0.78 mV. LAT-HA-LIP was isotonic (284.00 ± 1.41 mOsm L−1), had neutral pH (7.63 ± 0.01) and had suitable surface tension (44.07 ± 2.70 mN m−1) and viscosity (2.69 ± 0.15 mPa s−1) for topical ophthalmic administration. LAT-HA-LIP exhibited optimal in vitro tolerance in human corneal and conjunctival epithelial cells. No signs of ocular alteration or discomfort were observed when LAT-HA-LIP was instilled in albino male New Zealand rabbits. Hypotensive studies revealed that, after a single eye drop, the effect of LAT-HA-LIP lasted 24 h longer than that of a marketed formulation and that relative ocular bioavailability was almost three times higher (p < 0.001). These findings indicate the potential ocular protection and hypotensive effect LAT-HA-LIP offers in glaucoma treatment.SpringerUniversidad Complutense de Madrid20242024-04-1120242024-04-11journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/104619reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)InglésengAgencia Estatal de Investigación http://dx.doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-113281RB-C21 DISEÑO Y EVALUACION DE MICROESFERAS BIODEGRADABLES MULTIDIANA PARA LA TERAPIA DEL GLAUCOMAEuropean Commission http://dx.doi.org/10.13039/501100000780 Horizon 2020 Framework Programme 813440 Ocular Research By Integrated Training And Learningopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1046192026-06-02T12:44:21Z |
| dc.title.none.fl_str_mv |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| title |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| spellingShingle |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents Brugnera, Marco Glaucoma Hyaluronic acid Latanoprost Liposomes Ocular drug delivery Osmoprotectants Optica (Medicina) 2209.15 Optometría |
| title_short |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| title_full |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| title_fullStr |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| title_full_unstemmed |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| title_sort |
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents |
| dc.creator.none.fl_str_mv |
Brugnera, Marco Vicario De La Torre, Marta González-Cela Casamayor, Miriam Ana López Cano, José Javier Bravo Osuna, Irene Huete Toral, Fernando González Rubio, María Luisa Carracedo Rodríguez, Juan Gonzalo Molina Martínez, Irene Teresa Andrés Guerrero, Vanesa Herrero Vanrell, María Del Rocío |
| author |
Brugnera, Marco |
| author_facet |
Brugnera, Marco Vicario De La Torre, Marta González-Cela Casamayor, Miriam Ana López Cano, José Javier Bravo Osuna, Irene Huete Toral, Fernando González Rubio, María Luisa Carracedo Rodríguez, Juan Gonzalo Molina Martínez, Irene Teresa Andrés Guerrero, Vanesa Herrero Vanrell, María Del Rocío |
| author_role |
author |
| author2 |
Vicario De La Torre, Marta González-Cela Casamayor, Miriam Ana López Cano, José Javier Bravo Osuna, Irene Huete Toral, Fernando González Rubio, María Luisa Carracedo Rodríguez, Juan Gonzalo Molina Martínez, Irene Teresa Andrés Guerrero, Vanesa Herrero Vanrell, María Del Rocío |
| author2_role |
author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universidad Complutense de Madrid |
| dc.subject.none.fl_str_mv |
Glaucoma Hyaluronic acid Latanoprost Liposomes Ocular drug delivery Osmoprotectants Optica (Medicina) 2209.15 Optometría |
| topic |
Glaucoma Hyaluronic acid Latanoprost Liposomes Ocular drug delivery Osmoprotectants Optica (Medicina) 2209.15 Optometría |
| description |
The first line of glaucoma treatment focuses on reducing intraocular pressure (IOP) through the prescription of topical prostaglandin analogues, such as latanoprost (LAT). Topical ophthalmic medicines have low bioavailability due to their rapid elimination from the ocular surface. Nanotechnology offers innovative ways of enhancing the ocular bioavailability of antiglaucoma agents while reducing administration frequency. This study aims to combine LAT-loaded synthetic phosphatidylcholine liposomes with hyaluronic acid (0.2% w/v) and the osmoprotectants betaine (0.40% w/v) and leucine (0.90% w/v) (LAT-HA-LIP) to extend the hypotensive effect of LAT while protecting the ocular surface. LAT-HA-LIP was prepared as a mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dimyristoyl-sn-glycero-3-phosphocholine, cholesterol and α-tocopherol acetate. LAT-HA-LIP exhibited high drug-loading capacity (104.52 ± 4.10%), unimodal vesicle sizes (195.14 ± 14.34 nm) and a zeta potential of -13.96 ± 0.78 mV. LAT-HA-LIP was isotonic (284.00 ± 1.41 mOsm L−1), had neutral pH (7.63 ± 0.01) and had suitable surface tension (44.07 ± 2.70 mN m−1) and viscosity (2.69 ± 0.15 mPa s−1) for topical ophthalmic administration. LAT-HA-LIP exhibited optimal in vitro tolerance in human corneal and conjunctival epithelial cells. No signs of ocular alteration or discomfort were observed when LAT-HA-LIP was instilled in albino male New Zealand rabbits. Hypotensive studies revealed that, after a single eye drop, the effect of LAT-HA-LIP lasted 24 h longer than that of a marketed formulation and that relative ocular bioavailability was almost three times higher (p < 0.001). These findings indicate the potential ocular protection and hypotensive effect LAT-HA-LIP offers in glaucoma treatment. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2024-04-11 2024 2024-04-11 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/20.500.14352/104619 |
| url |
https://hdl.handle.net/20.500.14352/104619 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Agencia Estatal de Investigación http://dx.doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-113281RB-C21 DISEÑO Y EVALUACION DE MICROESFERAS BIODEGRADABLES MULTIDIANA PARA LA TERAPIA DEL GLAUCOMA European Commission http://dx.doi.org/10.13039/501100000780 Horizon 2020 Framework Programme 813440 Ocular Research By Integrated Training And Learning |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Springer |
| publisher.none.fl_str_mv |
Springer |
| dc.source.none.fl_str_mv |
reponame:Docta Complutense instname:Universidad Complutense de Madrid (UCM) |
| instname_str |
Universidad Complutense de Madrid (UCM) |
| reponame_str |
Docta Complutense |
| collection |
Docta Complutense |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403030314549248 |
| score |
15,300719 |